Wed, Oct 1, 2014, 10:03 AM EDT - U.S. Markets close in 5 hrs 57 mins

Recent

% | $
Quotes you view appear here for quick access.

CEL-SCI Corporation Message Board

  • bellami2000 bellami2000 Aug 12, 2013 10:42 AM Flag

    Until CVM reports successful enrollment complete

    The clock will not even start on phase3 trial. Until then it's nothing more than a money suck.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Hey bull... So what you're saying is ;any and all P3 clinical trials that are still recruiting have not started, correct?
      You're sure ?

      Bull is pumping on the INO M/B.
      Maybe she/he should check inovio on the clinicaltrials web site ( it's a gov site).

      Their trial that is recruiting ,according to YOU "will not start on phase 3 trial" until INO "reports successful enrollment complete"?

      BTW, TWO pivotal INOVIO P3 trials were HALTED by their respective "Data Monitoring Committee's recommendation."
      Is that a good thing?

      While YOU are reviewing INOVIO at the gov clinical trials site , take note of just how long some of those trials are taking. A LONG time, correct?

      ALSO when Inovio announced it was treating rodents for flu that was OK with YOU?
      If Cel-Sci's LEAPS was used to treat mice in a study that was conducted by N.I.A.I.D./N.I.H. , that's a bad thing?

      Have YOU noticed that INO wants to sell shares to raise money , thereby DILUTING , that's OK with YOU?

      People should sell their shares in the stock that YOU are dumping to buy the stock YOU are pumping?

      Buy the stock with two failed P3 clinical trials, that is treating rodents for the flu and has share holder dilution?

      Sentiment: Buy

 
CVM
0.9116-0.0001(-0.01%)9:58 AMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.